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a b s t r a c t
The greatest ambition and promise of tissue engineering is to manufacture human organs. Before “made-
to-measure” tissues can become a reality [1e3], however, three-dimensional tissues must be recon-
structed and characterized. The current inability to manufacture operational vasculature has limited the
growth of engineered tissues. Here, free-standing, small diameter blood vessels with organized cell
layers that recapitulate normal biological functionality are fabricated using microfluidic technology. Over
time in culture, the endothelial cells form a monolayer on the luminal wall and remodel the scaffold with
human extracellular matrix proteins. After integration into three-dimensional gels containing fibroblasts,
the microvessels sprout and generate extended hollow branches that anastomose with neighboring
capillaries to form a network. Both the microfabricated vessels and the extended sprouts support
perfusion of fluids and particles. The ability to create cellularized microvessels that can be designed with
a diameter of choice, produced by the meter, and undergo angiogenesis and anastomoses will be an
extremely valuable tool for vascularization of engineered tissues. To summarize, ultraviolet (UV) photo-
crosslinkable poly(ethylene glycol) and gelatin methacrylate polymers used in combination with sheath-
flow microfluidics allow for the fabrication of small diameter blood vessels which undergo neoangio-
genesis as well as other developmental processes associated with normal human blood vessel matura-
tion. Once mature, these vessels can be embedded; perfused; cryogenically stored and respond to stimuli
such as chemokines and shear stresses to mimic native human blood vessels. The applications range
from tissue-on-chip systems for drug screening, characterization of normal and pathologic processes,
and creation and characterization of engineered tissues for organ repair.
Published by Elsevier Ltd.
1. Introduction
Ideally, engineered human blood vessels should possess tunable
dimensions and be free standing so that they can be easily handled
and integrated into three-dimensional tissues, as well as be con-
nected to perfusion sources. The constructs should also be
amenable to storage for later use and self-sustaining in terms of
repair and angiogenesis [1e9].
Earlier attempts to produce vasculature for tissue models have
used de-cellularized cadaver materials as scaffolds [10], bio-
printing of large blood vessels [11], random outgrowth from
endothelial cell spheroid cultures or patterned microchannels
[12,13]. These approaches have been partially successful, yet fail to
provide both the range of microvessel diameters found in normal
vasculature and the desired control over microvessel placement
within a regenerating tissue [14e18]. A key challenge addressed
here is the creation of human vasculature that has not only
controllable size and cellular architecture but which can produce
new angiogenic growth for long term tissue sustainability, a feature
that many other technologies, including 3D printing, have yet to
fully realize.
Human vasculature forms through a series of developmental
processes. Endothelial sprouting from a main vessel (angiogenesis)
launches a network of smaller tubular branches each capable of
further sprouting to support blood flow (tubulogenesis). Critical
junctions (anastomoses) between arterial and venule capillary beds
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establish a network of arteries/veins, arterioles/venules and capil-
laries [19]. These three combined processes are essential for tissue
maintenance, yet have not been fully replicated in synthetic sys-
tems. To date, these processes have largely been accomplished
using endothelial spheroid cultures embedded in matrices or pre-
patterned microchannels and have not yet been observed from
free-standing porous synthetic blood vessels.
The objective of this study is to develop an efficient method of
constructing human blood vessels that are both representative and
complimentary to microscale human blood vessels. Preferably,
these fabricated vessels would then support the formation of a
primitive network of blood vessels via the natural processes of
angiogenesis, tubulogenesis and anastomosis (Fig. 1), and we
sought to characterize the developmental events that occur using
our technology. The experimental design begins by creating HEMVs
with a desired diameter via hydrodynamic focusing. When seeded
into a three-dimensional matrix, the human endothelial micro-
vessels (HEMV) initiate neovascularization which proceeds from
angiogenesis through anastomosis. As HEMV technology creates
hollow tubular structures with cellular components in place, the
ability to immediately perfuse tissue eliminates significant delays
associated with tubular development from endothelial networks
derived from spheroid cultures. Furthermore, as the HEMV is
constructed using a micro-porous [20], biodegradable material,
removal of the scaffold is not required. These advantages, together
with the possibility for long term storage of HEMV, make the HEMV
technology highly useful for in vitro tissue engineering and tissue-
on-chip analytical systems.
2. Materials and methods
2.1. Fabrication of microvessels
Microvessels were produced using the microfluidic fabrication
method previously described [20e22] with minor modifications.
Briefly, poly(ethylene glycol) (PEG) tetrathiol and poly (ethylene
glycol) acrylate were purchased from JenKem USA (Allen, TX) and
resuspended at a 1:1 M ratio in a 1X phosphate buffered saline
solution containing 0.4% Irgacure2959 Sigma Aldrich (St. Louis,
MO). Gelatin-methacrylamide (GelMA) has been widely identified
as a successful substrate for cell attachment in a multitude of
bioengineering applications [23,24]. Synthesis of GelMA, using
porcine-derived gelatin Sigma Aldrich (St. Louis, MO) was per-
formed as previously described [20] and lyophilized gelatin-
methacrylamide was included in the previously mixed PEG poly-
mer also at a 1:1 ratio to provide support for cellular attachment.
The final concentration of the mixed polymers is 6% w/w (3%
poly(ethylene glycol) and 3% gelatin-methacrylamide). Purified
protein components include a mixture of fibronectin (50 mg/mL)
from Corning (Bedford, MA), rat-tail collagen-1 (75 mg/mL) and
hyaluronic acid (18 mg/mL), both from Sigma Aldrich (St Louis, MO),
were added to supplement the poly(ethylene glycol)/gelatin-
methacrylamide mixture and further support cellular attachment.
The outer sheath fluid is 6% PEG, resuspended in phosphate buff-
ered saline. Cells comprising the lumen are resuspended in a 1%
non-photo-crosslinkable gelatin solution; while cells placed in the
polymer wall are directly added to the polymer solution. Flow rates
for were as follows. Outer sheath 90 ml/min; polymer comprising
the microvessel wall 29 ml/min and inner lumen flow is 15 ml/min.
2.2. Microvessel cryopreservation
Day 8 HEMVs were examined for the ability to recover from
cryopreservation in three replicate experiments. Briefly, HEMV
were removed from the incubator and immediately transferred to
cryovials containing endothelial freezing medium (80% EGM-2, 10%
fetal bovine serum, 10% dimethyl sulfoxide). Cryovials were then
placed into a freezing chamber and transferred to80 C overnight.
Fig. 1. Neovascularization strategy and implementation. 1. Human endothelial cells (EC) are encapsulated in a bio-macromolecular tubule using a hydrodynamic shaping device. The
resultant human endothelial microvessel (HEMV) matures with a coherent endothelial cell lumen. Temporal events a-e (left) correspond to experimental micrographs (right). (a)
Representative composite image of ten adjacent fields (10X) taken along the length of a single HEMV immunostained with anti-CD31 (green) demonstrates the ability to produce
long continuous HEMVs. Scale, 500 mm; inset 50 mm (b) A confluent monolayer of endothelial cells form along the luminal face of the microvessel. 2. Once embedded in a three-
dimensional matrix, the HEMV develop a primitive microvasculature network through traditional vascularization processes, (c) HEMV angiogenesis, the sprouting of endothelial
growths from the original HEMV into an extracellular matrix containing dermal fibroblasts (DAPI-stained nuclei, blue), (d) HEMV tubulogenesis (arrowhead), the hollowing of
sprouts to support fluid transport, (e) HEMV anastomosis, a developmental process whereby neighboring sprouts form connections (arrowheads) establishing a closed-loop system
for circulation. Scale, (b þ d) 25 mm; (c þ e) 50 mm.
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Cryovials weremoved to a liquid nitrogen storage dewar and placed
into vapor-phase storage for 24 h. HEMVwere then thawed at 37 C
and immediately placed into complete growth medium and
allowed to recover for 24 h at 37C/5% CO2. As a note, suspending
HEMV in freezing media and immediately submerging the vial in
liquid nitrogen resulted in HEMV structural failure and micro-
vessels were not recoverable. As a positive control for cell death,
HEMV were fixed in 10% neutral buffered formalin for 3h and then
permeabilized in 1X phosphate buffered saline/0.5% Triton X-100
for 1h, room temp. Cell viability was then examined using Live/
Dead® assay ThermoFisher Scientific (Grand Island, NY). 20X im-
ages were captured and both live and dead cells were counted and
plotted as a ratio of total number of cells. For the inflammatory
cytokines assay, native or cryopreserved HEMV were treated with
either TNF-a (25 ng/mL) or IL-1b (2.5 ng/mL) EMD Millipore (Bill-
erica, MA) for up to 4 h. Cryopreservation was performed as re-
ported above, with cytokine treatment performed on fully
recovered HEMV and done in parallel with native microvessels.
Real-time quantitative PCRwas then used to assay the expression of
the Pe and E-selectin genes; with GAPDH as control. The statistical
analyses depicted (ANOVA) compare each time point to the
matched untreated (0 h) control.
2.3. Cell/vascularization experiments
2.3.1. Human cells and growth media
Primary human umbilical vein endothelial cells and primary
human dermal fibroblasts were obtained from Lonza (Walkersville,
MD) and passaged as recommended. Endothelial growth medium-
2 with required supplements (Lonza) was used to grow endothelial
cells; while fibroblasts were cultured in DMEM plus 10% fetal
bovine serum ThermoFisher Scientific (Waltham, MA). Human
primary vascular smooth muscle cells were obtained from ATCC
(Manassas, VA) and grown in DMEM/F12 (1:1) with 10% fetal
bovine serum plus endothelial growth factor supplement (Sigma),
along with the buffers sodium selenite, sodium bicarbonate as
recommended. Human vascular pericytes were obtained from
ScienCell (Carlsbad, CA) and grown in DMEM/F12 growth medium
containing 10% fetal bovine serum. All cells were maintained at
37 C in 5% CO2 and not used for experimentation beyond passage
five. Cells were deemed negative for mycoplasma contamination
using MycoProbe R&D Systems (Minneapolis, MN). For microvessel
construction, 3  107/mL endothelial cells were used to form the
lumen of both single- and multi-cell microvessels; 5  106/mL
smooth muscle cells and pericytes were grown in separate cultures
and then combined (1:1 ratio) to form the multi-cell microvessels.
Multi-cell microvessels containing HUVEC/SMC/HVP were main-
tained in 50% composite growth media containing 50% EGM2
(Lonza) and 50% DMEM/F12 10%FBS as both SMC and HVP were
maintained using this medium.
2.3.2. Antibodies
Monoclonal anti-CD31 (Ab-1) was obtained from ThermoFisher
(Waltham, MA) and used at a 1:200 dilution; anti-VE-cadherin was
obtained from Santa-Cruz Biotechnology (Dallas, TX). Secondary
antibodies were Alexa-488 and Alexa-594 and used at 1:1000 Life
Technologies (Grand Island, NY). Anti-collagen IV (clone COL-94)
was used at 1:500; anti-laminin was used at 1:100; anti-collagen
VII (LH7.2) was used at 1:500, all were obtained from Sigma
Aldrich (St. Louis, MO). Anti-porcine-specific collagen I/III (C7510-
18Q) was used at 1:25 as recommended by manufacturer USBio-
logical (Salem, MA). Phosphorylated-Smad2 (Ser465/467)/Smad3
(Ser423/425) (clone D27F4) was obtained from Cell Signaling Tech-
nologies (Danvers, MA). Anti-Ki-67 (clone 35) was obtained from
BD Biosciences (San Jose, CA). Anti-alpha-smooth muscle actin (a-
SMA; PA5-16697) was obtained from ThermoScientific. Neural glial
antigen-2 (NG2) was obtained from Millipore (Billerica, MA) and
used at 1:100 as recommended. Anti-E-selectin (clone 1.2B6) was
obtained from ThermoFisher (Waltham, MA) and was used at 2 mg/
mL.
2.3.3. Confocal microscopy/fluorescence quantitation
Image capture was performed using a Nikon laser scanning
confocal microscope; Nikon Elements and Adobe Photoshop soft-
ware were used for image rendering. At least five representative
regions of interest were captured over each triplicate experiment
and used for quantitative analyses using mean fluorescence in-
tensity determined using ImageJ (NIH) as previously reported
[25,26]. Images of secondary-only negative controls were also
collected and used for the purposes of background fluorescence
quantitation.
2.3.4. Angiogenesis assays/immunofluorescence
HEMVs were constructed and placed in a CO2 incubator for 7
days to allow attachment/growth of endothelial cells to the inner
luminal face of microvessel. Primary dermal fibroblasts have been
shown to facilitate angiogenesis [27,28]. Therefore, fibroblasts were
trypsinized, collected and counted and resuspended at
5  105 cells/mL in the hydrogel solutions described below. Using
surgical forceps and scissors, microvessels were first cut into
shorter lengths then transferred to either 24-well cell culture plates
or glass coverslips (coverslips were used for high magnification
confocal imaging). Microvessels were then overlaid with solutions
of either 4% gelatin-methacrylamide/0.5% photoinitiator (PI) or
growth factor reduced Matrigel® BD Biosciences (San Jose, CA)
containing primary fibroblasts, plus recombinant human vascular
endothelial growth factor (rhVEGF, 60 ng/mL) and basic fibroblast
growth factor (bFGF, 30 ng/mL). Gelatin-methacrylamide was
photopolymerized with UV light (10 mW/cm2, 5 s); Matrigel®was
allowed to cure at 37 C for 1hr. Four individual microvessels were
used in three separate experiments; the results presented are
representative of the biological replicates. Cell-laden microvessels
were maintained in growth media and were harvested after 17e21
days unless otherwise indicated; growth media was replaced with
fresh media every other day. The above protocol was replicated for
HEMV tissue constructs lacking dermal fibroblasts. At the end of the
growth period, microvessels were fixed in 4% neutral buffered
formalin for 1hr, on ice, followed by permeabilization in 1X phos-
phate buffered saline/0.5% TritonX-100 for 30 min, on ice. Immu-
nofluorescence was performed as previously reported [25]. Briefly,
pre-diluted primary antibody was added to the microvessels and
incubated overnight, 4 C. The following day, microvessels were
washed 3X in phosphate buffered saline containing 0.05% Tween-
20 (PBS-T) and then incubated in secondary antibody for 3 h at
room temperature. Finally, DAPI was added at the end of the in-
cubation period for 5 min, and microvessels were extensively
washed in PBS-T.
Transforming growth factor-beta (TGF-b) is a critical signaling
pathway involved in angiogenesis [29]. Therefore, the ability of the
TGF-beta pathway to become activated in the HEMVwas addressed
using purified TGF-beta growth factor. HEMV were serum starved
overnight and the following day 5 ng/mL recombinant human TGF-
b R&D Systems (Minneapolis, MN) was added to HEMV for 10min.
HEMV were then fixed and stained for p-Smad2/3.
Neural glial antigen-2 (NG2) has been previously shown to
identify human pericytes at least initially, however in the presence
of other cell types such as smooth muscle cells (SMC), pericytes can
readily transdifferentiate into SMC [30e33]. To address neural glial
antigen-2 (NG2) expression over time, 100  103 human vascular
pericytes (HVP) were plated at confluency into 24-well plates and
K.A. DiVito et al. / Biomaterials 138 (2017) 142e152144
maintained either as a mono- or co-culture with smooth muscle
cells (SMC). For co-culture, HVP and SMC were mixed at a 1:1 ratio
and cultured over a 7 day time course, with daily media changes.
Cells from day 1 and day 7 were then fixed in 4% neutral buffered
formalin and immunostained simultaneously using either anti-NG2
or anti-a-SMA overnight at 4 C. Five separate 20X images, repre-
senting >500 cells were captured for each condition and mean
fluorescence intensity was determined using ImageJ (NIH) after
normalizing to cell number. The mean fluorescence intensity for
NG2 or a-SMA was then plotted for both the mono- or co-culture
conditions.
2.4. Microvessel cannulation/perfusion experiments
Microvessel perfusion was executed using either of two ap-
proaches. For the cannulation experiments, three HEMVs were
placed onto separate glass coverslips and, microvessels were
overlaid with 4 % gelatin-methacrylamide/0.5 % Igracure-2959 and
photopolymerized to immobilize while leaving both termini
exposed for cannulation and flow-through. Polycarbonate micro-
capillaries with dimensions of 80 mm OD/53 mm ID Paradigm Op-
tics (Vancouver, WA) were then manually threaded into the
microvessel with the aid of a dissecting microscope while keeping
the microvessel hydrated in phosphate buffered saline. Connec-
tions were made via threading the capillary into a Luer-Lok tip
attached to a 1 mL syringe; the syringe was then loaded into a
syringe pump Harvard Apparatus (Holliston, MA). Once the
microvessel was cannulated, perfusion was initiated in a stop-flow
fashion using a 1 mL/min flow rate; flow was permitted for
approximately 2min. For cannulation experiments, fluorescent Nile
Redmicroparticles (NRmp, 0.52 mmOD) SpheroTech (Lake Forest, IL)
were used at 1:100 in 1X phosphate buffered saline. Microvessels
were then imaged using confocal microscopy. For perfusion of live
cell-laden microvessels, a novel manifold device was constructed
by casting polydimethylsiloxane (PDMS) into micro-milled
aluminum molds. Once cured, the device was then delaminated,
microvessels were removed from the CO2 incubator and placed in
between polydimethylsiloxane pillars of the mold designed to hold
the microvessels in place under perfusion. For sealing the devices, a
2  3 inch glass slide Fisher (Pittsburgh, PA) and the poly-
dimethylsiloxane device were plasma coated using a hand-held
corona treater from Electro-Technic Products (Chicago, IL) and
immediately sealed. The center cavity of the device was filled with
4% gelatin-methacrylamide/0.5% photoinitiator through existing
biopsy punches present on the device; gelatin-methacrylamidewas
then photopolymerized. Inlet cavities were then perfused with
endothelial growth media via a micro-peristaltic pump; mediate
was recirculated by collecting perfusate from the outlet present on
the device. Flow was introduced at 3.1 mL/min, which corresponds
to a shear rate of 4.2 dyn/cm2 of observed shear stress. Manifold
devices were transferred to a 37C/5% CO2 incubator to maintain
cell viability; growth media was also placed into the incubator and
left uncapped to permit gas exchange. Perfusion fluids continually
recirculated for the times indicated.
2.5. COMSOL simulations
Simulations for shear rate and shear flow were performed using
finite-element analysis software COMSOL Multiphysics® (Burling-
ton, MA). Cylindrical models with an extra fine mesh density and
diameters of 125 and 100 mmwere used as a representation of the
microvessel lumen. The parameters for viscosity and density were
set at 7.8 104 Pa s and 1007 kg/m3, respectively [34]. Calculations
for shear rate were carried out for flow rates ranging from 20 mL/
min to 0.5 mL/min.
2.6. Quantitative RT-PCR
Total RNA was collected from four individually perfused
microvessels in each of three separate experiments by dismantling
the polydimethylsiloxane device, harvesting the embedded
microvessels and transferring to TRIzol® reagent Life Technologies
(Grand Island, NY). Real-time PCR was performed using a two-step
method. RNA was quantitated via NanoDrop™ and 175 mg of total
RNA was used for first strand cDNA synthesis via SuperScript IV,
which was followed by real-time PCR performed using Power
SYBR™ Green master mix, both Life Technologies (Grand Island,
NY). Quantitative PCR was performed using an Applied Biosystems
instrument (Carlsbad, CA). Analyses of RT-PCR data was performed
using the delta-delta Ct method following amplification efficiency
analysis using 10-fold dilutions of template cDNA, as previously
described [25]. Custom oligos were purchased from Eurofins Ge-
nomics (Huntsville, AL). A list of corresponding oligo sequences can
be found in Table S1.
2.7. Statistics
All plots, normality testing and statistical analyses were gener-
ated using OriginPro 8.5 OriginLab Corporation (Northampton,
MA). Asterisks represent results from either two-sided Student's t-
test, or ANOVA along with Tukey post-hoc means comparison,
where *p < 0.05; **p < 0.01; ***p < 0.001.
2.8. Data in brief
Data describing media compatibility experiments for all the
relevant cell types, the denuding of the polymeric shell of the
microvessel and information regarding microvessel composition
and construction have been submitted as a Data in Brief article [35].
3. Results and discussion
3.1. HEMV fabrication and characterization
The HEMV microfabrication process uses hydrodynamic
focusing to surround a continuous flow of suspended cells with a
biocompatible hydrogel network [20,36,37]. This fabrication pro-
cess (Fig. S1) incorporates single or multiple cell types into discrete
regions of the microvessel during assembly. The length of HEMV
produced is limited only by the volume of source materials and, in
this study, continuous production of greater than 1m of HEMVwith
an inner diameter (I.D.) of 125 mm is obtained in each experimental
run. The hydrodynamic focusing technique also facilitates HEMV
dimensional tuning by controlling fluid flow rates [20]. In consid-
eration for potential clinical and translational applications, an outer
diameter (O.D.) of 250 mm was selected to obviate the need for
specialized handling tools during manipulation.
Human umbilical vein endothelial cells are introduced in the
lumen of the HEMV during fabrication; cellular attachment to the
luminal wall is observed after 3 days. Cell expansion continues until
a confluent monolayer is apparent by day 10 (Fig. 2a). Arterioles
contain multiple cell types and are modeled by introducing
vascular smooth muscle cells and pericytes into the wall of the
microvessel during the fabrication process and are referred to as
multi-cell microvessels (MCMV). The endothelial cells line the
lumen, while smooth muscle cells proliferate to fill the abluminal
wall by days 7e10, with continual growth through days 15e20
(Fig. 2a; Fig. S2) and beyond.
Characterization of the HEMV with laser-scanning confocal
immunofluorescence microscopy (LSCM) determines the expres-
sion and localization of biomarker proteins in HEMV at various time
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points. Cells in the luminal wall of the HEMV expressed the
endothelial biomarker CD31 and vascular endothelial-cadherin
(VE-cadherin) (Fig. 2b and Videos S1, S2). For MCMV, media
compatibility assays determined the composite growth media
required to support each cell type and a 50/50 composite formu-
lationwas used for experimentation, these data can be found in our
companion paper [35]. Immunofluorescence staining identifies the
cell types incorporated into the MCMV (Fig. S2a). Alpha-smooth
muscle actin (a-SMA) is expressed by both smooth muscle cells
(SMC) and pericytes, while neural glial antigen-2 (NG2) has been
shown to identify pericytes. Yet, both of these cell types are closely
linked and transdifferentiation of pericytes into smooth muscle
cells has been observed making cell fate tracking difficult
[30,38e41]. Using an in vitro co-culture assay, we address
biomarker expression over time (Fig. S2b) and find that NG2
expression, while a viable marker for pericytes in mono-culture,
was reduced after 24 h and further reduced by up to 2.5-fold
(p < 0.01) day 7 in co-culture with smooth muscle cells, indi-
cating that NG2 expression is likely not suitable to distinguish
pericytes from the smooth muscle cells used to create the MCMV.
Nevertheless, this multi-compartmental strategy enables the
placement of multiple cell types into the microvessel without dis-
rupting the structural integrity of the MCMV during initial cell
expansion.
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.biomaterials.2017.05.012.
Downstream applications such as in vitro tissue constructs
require de novo synthesis of human derived proteins. Therefore, the
time-dependent deposition of extracellular matrix proteins
including collagens IV, VII and lamininwere evaluated. Twelve days
after fabrication (T0), striking expression of both human collagen IV
(6.5-fold; p < 0.001) and human laminin (>13-fold; p < 0.001) were
observed in thewalls of the HEMV (Fig. 2c and d). As a control, skin-
associated [42] collagen VII was assayed and found undetectable at
T0 and day 12 (Fig. S3a). Further, a significant decrease (>2-fold;
p < 0.001) in the porcine-derived collagen I/III, originally included
in the HEMV scaffold, was observed after 30 days, when compared
to T0 (Fig. S3b).
VE-cadherin is a critical biomarker integral for the long-term
maintenance of microvessels. Expression of VE-cadherin iden-
tifies adherens junction formation in the HEMV by day 10, with
persistent expression through day 120 (Fig. 3a). Further, HEMV
maintain their hollow tube morphology (Figs. 2b and 3a), a feature
indispensable for proper vascular perfusion. Taken together, VE-
cadherin indicates cells establish proper cell-cell junctions; while
de novo human collagen IV and laminin accumulation, along with
reduced porcine-derived collagen, indicate resident cell pop-
ulations of the HEMV progressively remodel their environment by
depositing matrix proteins and replacing exogenous materials.
Remodeling of the surrounding matrix is essential for promoting
structural integrity, initiating angiogenesis and subsequent
vascular expansion.
3.2. HEMV preservation and response to biological cues
Reliable HEMV fabrication and storage could enable a transition
toward rapid manufacturing of vascularized tissue constructs.
Recently, induced pluripotent stem cell (iPSC) technology has suc-
cessfully differentiated endothelial cells from dermal fibroblasts
[2]. As demand for personalizedmedicine increases, tailored-HEMV
could be prospectively constructed and banked for future use via an
iPSC source. To that end, cryopreserved HEMV was evaluated
Fig. 2. Characterization of cell-laden HEMV. (a) Top, depicts a 20-day time course showing endothelial cell attachment to the inner luminal face of the HEMV, forming vessel mimics
similar in size and cellularity to capillaries and venules. Lower, multi-cell microvessel composed of endothelial cells (lumen) and smooth muscle cells/pericytes (outer-walls) creates
an arteriole-like mimic. Scale, 50 mm. Arrowheads depicts smooth muscle cell/pericyte placement and outgrowth in walls. (b) Laser scanning confocal microscopy identifies cell
surface protein expression in day 12 HEMV. Endothelial cells express both CD31 (green) and VE-cadherin (red), confirming the cell type and the presence of critical adherens
junctions necessary for proper endothelial function. CD31 (green); VE-cadherin (red); DAPI (blue nuclear stain) overlay is also shown. Both orthogonal and 3D views confirm the
hollow, tubule morphology of the created HEMV. Scale, 50 mm (c and d) Anti-collagen IV and anti-laminin show accumulation of newly secreted human matrix protein. Top panels
show representative HEMV at time zero (T0); bottom panel shows microvessels analyzed at day 12. Day 12 HEVM were observed with a 6.5-fold increase in collagen IV (p < 0.001);
similarly laminin exhibited a 13-fold increase in expression (p < 0.001) when compared to T0 microvessels. Scale, 100 mm.
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initially for cell viability and subsequently for the ability of the
recovered constructs to exhibit normal endothelial cell functions
(Fig. 3bec). Live/dead staining reveals no statistical change in per-
centage of dead cells following recovery from cryopreservation.
A critical aspect of functional vasculature is response to in-
flammatory signals delivered to endothelial cells via circulating
inflammatory cytokines [43]. To further characterize the HEMV
technology, a response to inflammation assay was measured using
quantitative-PCR on both native and cryopreserved day 8 HEMV
(Fig. 3dee). Cytokines such as tumor necrosis factor-alpha (TNF-a)
and interlukin-1beta (IL-1b) are critical pro-inflammatory signaling
molecules responsible for triggering endothelial expression of
leukocyte adhesion genes such as E-selectin. Native or cry-
opreserved HEMV treated with either TNF-a or IL-1b increased E-
selectin production up to a 40-fold increase (p < 0.001) and up to a
12-fold increase (p < 0.001), respectively, when compared to un-
treated control HEMV. In most cases, E-selectin was strongly
elevated 2 h post treatment with reduced expression observed by
4 h. The observed expression was evident either in the presence or
absence of cryopreservation; the only statistical significance be-
tween those groups was identified following IL-1b (2 h) treatment,
where the cryopreserved group indicated a slightly more potent E-
selectin response (p< 0.01) compared to the native HEMV (2 h). The
observed effects are consistent within time frames and concen-
trations reported for human endothelial cells [44e47]. A similar
upregulation of E-selectin protein is exhibited following treatment
with TNF-a or IL-1b. P-selectin preferentially responds to the clot-
ting factor thrombin [47,48] and was not induced over the time
course assayed and serves as a negative control. These data provide
not only functional assessment regarding gene expression in
HEMVs following cryopreservation, but also provide valuable in-
formation regarding the ability of both native and cryopreserved
HEMV to stimulate genes necessary for leukocyte attachment in
response to inflammatory signals.
Endothelial cell proliferation and cell-signaling pathway acti-
vationwere also assayed to determine if cells in HEMV recapitulate
normal cellular functions. To address primary cell proliferation and
quiescence following cell integration, the Ki-67 nuclear prolifera-
tion marker was assayed. At time zero (T0), >70% of resident
endothelial cells are actively undergoing replication evidenced by
nuclear expression of Ki-67. The Ki-67 expression is coupled with
minimal cell-surface expression of VE-cadherin (Fig. S4a), indi-
cating that the endothelial cells have not yet exhibited contact in-
hibition. Once continuous cell-cell contacts are established, Ki-67
expression is reduced 3.5-fold (p< 0.001) and a concomitant potent
increase in VE-cadherin is observed at the homotypic cell-cell
Fig. 3. Long-term HEMV viability, cryopreservation and response to inflammation. (a) Representative HEMV grown for 120 days in growth-media suspension and immunostained
with anti-VE-cadherin (red); DAPI (blue) identifies nuclei. VE-cadherin is expressed at the cell surface and structural integrity of microvessel is maintained as shown via 3D confocal
images. In addition, small endothelial sprouts can be observed at the periphery of the lumen, indicating potential neoangiogenesis while in suspension. Scale, 50 mm (b and c) Live/
dead assay performed on native, cryopreserved (CP), or formalin-fixed HEMV (day 8). Live cells (green); dead cells (red). Insets to the right of each image show orthogonal images
depicting the hollow structure of representative HEMV for each condition. No statistical change in percentage of dead cells was observed following recovery from cryopreservation.
Scale, 50 mm (d and e) To assess the ability of HEMV to respond to inflammatory signals, native () or cryopreserved (þ) HEMV were treated with either tumor necrosis factor-alpha
(TNF-alpha) or interleukin-1beta (IL-1beta) for the indicated times. Real-time PCR identifies up to a 40-fold increase (p < 0.001) in E-selectin gene expression following TNF-alpha
treatment and, similarly, up to a 12-fold increase (p < 0.001) following IL-1beta treatment. Statistical assessments shown compare experimental (2h, 4h) to matched (0h) untreated
control. Adjacent immunofluorescence images depict increased expression of E-selectin (green) following the respective treatment. DAPI (blue) Scale, 50 mm.
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junctions. This pattern is consistent with the process whereby
normal mammalian cells undergo contact inhibition and enter a
reversible phase of the cell-cycle (quiescence) to avoid over
proliferation.
Furthermore, to validate that cells in the HEMV recapitulate
other normal functions, we interrogated the transforming growth
factor-beta (TGF-b) signaling pathway as it is directly involved in
angiogenesis [29]. Activation of the TGF-b pathway via the surro-
gate marker phosphorylated-Smad2/3 [49] indicates TGF-b-treated
HEMV strongly induces Smad2/3 phosphorylation, resulting in
nuclear retention (Fig. S4b). Consequently, cells present in the
HEMV proliferate until confluent, establish cell-cell adherens
junctions and activate signaling pathways, which are three signif-
icant indicators of a biologically functional blood vessel.
3.3. Neoangiogenesis
In the absence of angiogenic potential, incorporation of vascu-
lature alone is insufficient to support complex tissue as simple
diffusion is inadequate for nutrient transport beyond 1 mm [50,51].
Therefore, organized endothelial expansion beyond the primary
HEMV is necessary to sustain three-dimensional tissue constructs.
We hypothesized that denuding the biopolymeric shell of the
HEMV might be required for neoangiogenesis and we successfully
denuded day 7 HEMV via collagenase digestion or mechanical
disruption [35].
However, further examination of intact HEMV revealed short
protrusions extending into the surrounding biopolymeric shell
(Fig. 3a), which suggested that resident endothelial cells could
undergo angiogenic sprouting through the synthetic microvessel
wall. Further studies thus focused on supporting the angiogenic
potential of the intact HEMV by embedding them in a hydrogel
containing normal human dermal fibroblasts to mimic a tissue
environment. Endothelial cell-only HEMV provided the opportu-
nity to characterize endothelial expansion and endothelial sprouts
easily distinguished from the fibroblasts present in the surrounding
gel. Under these conditions substantial endothelial sprouting
(Fig. 4aec) was observed when embedding intact HEMV in the
presence of primary fibroblasts.
Two different types of hydrogel, both containing dermal fibro-
blasts, were investigated for incorporation of the HEMV into a
model tissue. Growth-factor-reduced Matrigel® or 4% gelatin-
methacrylamide both supported endothelial expansion from the
HEMV with no marked difference observed in overall sprouting
performance. Matrigel® slightly increased the average number of
endothelial sprouts, though this did not reach statistical signifi-
cance (p > 0.59). Thus, while maintaining microvessel integrity
after removing the polymer walls is feasible [35], it is not required
as the HEMV clearly exhibit prolific neovascularization using as-
fabricated microvessels.
Further, embedded HEMV retain the hollow-tubule
morphology, indicating HEMV structural stability (Fig. 4a).
Dimensionally, sprouts are wider closest to the microvessel and
narrow to <8 mm in width at sprout termini. Sprout lengths
measured from the outer edge of the HEMV to the advancing tip
ranged from 50 mm to 1290 mm (Fig. 4c) with a median length of
547 mm; shorter assay times resulted in shorter overall lengths,
indicating that 1.3 mm may not be the upper limit of growth.
Remarkably, endothelial sprouts were also observed to traverse the
synthetic wall of the HEMV (Fig. 4a; Figs. S5aed), a critical feature
essential for vascularization and ultimate tissue integration.
Furthermore, observed interactions between neighboring
embedded HEMVs, via capillary outgrowth, indicates putative
HEMV-HEMV linkages (Fig. S5d).
Having observed HEMV neoangiogenesis, we next verified that
the newly-formed sprouts were hollow tubules. Fig. 4d (center)
depicts a representative CD31þ angiogenic sprout, while flanking
insets show representative high-magnification images. Orthogonal
laser scanning micrographs confirm the hollow nature of the
sprouts with an average luminal diameter of 4±1 mm. Extensive
CD31þ filiopodial projections are observed along the lengths of
many sprouts and are indicative of continued endothelial expan-
sion (Fig. 1d; 4d-e). Anastomoses among angiogenic sprouts were
virtually innumerable (Fig. 4e), pointing toward terminal devel-
opment of a complex vascular network. Further, fibroblasts play an
integral role in angiogenesis by providing matrix remodeling
necessary for endothelial outgrowth, and organized DAPI-labeled
fibroblasts were observed upstream of the advancing CD31þ
bifurcated endothelial tip (Fig. S5c), results consistent with previ-
ous observations [27,28].
The growth status and efficacy of dermal fibroblasts included in
the extracellular matrix of HEMV tissue constructs was also
assessed. Similar to CD31, we find VE-cadherin expression is
maintained on endothelial sprouts derived from HEMV embedded
in a fibroblast matrix (Fig. S6a) indicating sprouts support cell-cell
adhesions. Using Alexa488-phalloidin to identify cytoskeletal F-
actin, embedded fibroblasts display a spheroidal morphology at
time zero, as expected. By day 5, fibroblasts present in the hydrogel
display characteristic bipolar, elongated morphology consistent
with viable fibroblast expansion (Fig. S6b) [52]. When fibroblasts
were excluded, endothelial sprouting was found to be significantly
reduced with only short projections of 27 mm median length
observed nearest the HEMV lumen at the time of collection on day
21 (Fig. S6c). In the absence of fibroblasts, CD31þ endothelial
sprouts failed to exit the polymer wall of the HEMV by the time
point assayed, indicating that fibroblasts were integral to the
development andmaturation of endothelial sprouting derived from
the HEMV.
3.4. HEMV perfusion and shear stress response
To investigate whether sprouts support perfusion, embedded
HEMV were cannulated using polycarbonate capillaries (Fig. S7).
The HEMV remained viable under approximate pressures of
150e2500 Pa without failure and were able to withstand shear
stresses up to the flow-rate limits of the peristaltic pump (25 dyn/
cm2). Three distinct regions of interest are used to illustrate
perfusion (Fig. S7b). Insets show that NRmp enter newly formed
sprouts, confirming the HEMV are hollow and support fluid
transport. However, not all angiogenic sprouts were identical
(Fig. S7c); NRmp are present in the lumen of CD31þ positive endo-
thelial sprouts but absent in immature or otherwise occluded
sprouts, with NRmp exclusion likely due to ongoing sprout devel-
opment, as has been previously observed [53,54]. On average,
mature sprouts supporting perfusion were found to outnumber
immature sprouts by a ratio of 3:1.
Finally, shear stress was investigated to validate the HEMV
method of neovascularization (Fig. S8; Videos S3a and b) using both
experimentally derived observations as well as COMSOL simula-
tions. Not only does shear stress generate forces that act upon the
vessel, but cells undergo morphological changes in response to
pulsatile perfusion. Therefore, to illustrate that HEMV support
perfusion in a microvessel containing living cells, a novel manifold
device [52,55] in conjunction with a peristaltic pump was used to
recirculate either growth media or Nile Red microparticles through
individual microvessels.
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.biomaterials.2017.05.012.
Genes related to shear stress have been widely investigated, in
more rigid models, with links to multiple cell signaling pathways,
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including TGF-b [56]. TGF-b itself has pervasive effects upon
cellular growth dynamics and can effect proliferation, differentia-
tion, migration and blood vessel maturation. TGF-b stimulates
various response genes called Smads that either propagate or
inhibit the TGF-b signal. Smad6 and Smad7 are inhibitory-Smads (I-
Smads). Smad6 limits the signaling of the bone morphogenetic
protein (BMP) receptor, while Smad7 predominantly inhibits TGF-b
[57e59]. Changes in expression of other genes such as Krüppel-like
factor-2 (KLF2); chemokine receptor-4 (CXCR-4); sphingosine
kinase-1 (SPHK1); sphigosine-1-phosphate phosphatase-1
(SGPP1); and sphingosine-1-phosphate lyase-1 (SGPL1) have also
been explored in response to shear stress [60,61] and are investi-
gated here using live, cell-laden HEMV to in order validate the
model. Interestingly, differential gene regulation occurred within a
relatively short time frame (1h or 3h) (Fig. 5) suggesting that
perfusion has an earlier effect on cellular dynamics than previously
reported [61e63]. The most prominent changes are observed in
SMAD7, KLF2 and SPHK1 with 3.5-, 4.5- and 3.1-fold increases
respectively (p < 0.001). Conversely, SMAD6 and SGPL1 were
downregulated 3.8- and 1.7-fold (p < 0.001; p < 0.05), respectively,
after 1h of perfusion. Furthermore, the differential effects observed
between SMAD6 and SMAD7 under perfusion assays are
noteworthy. Shear stress likely targets the BMP pathway for
enhanced expression, observed here as relieved repression; while
conversely TGF-b activation is inhibited via SMAD7, indicating TGF-
b may not be required by endothelial cells under shear-stress, an
observation supported in other work [64]. Also, the slight repres-
sion of SGPL1 observed here is consistent with the increases
observed in SGPK1, as SGPL1 functions as a negative regulator of
SPHK1.
Finally, genes such as EphrinB2 (EFNB2) and EphB4 (EPHB4) have
previously been shown to function as biomarkers capable of
differentiating between arterial and venous blood vessels [65e68].
Arterial-derived blood vessels have been shown to express the
transmembrane ligand EphrinB2, while venous-derived vessels
have been shown to express EphB4, the cognate receptor for Eph-
rinB2. In order to determine if EphrinB2 or EphB4 can be used to
distinguish HEMV and MCMV under perfusion, live HEMV or
MCMV were exposed to shear stresses for up to 2 h (Fig. 5dee) and
RNA was assessed via quantitative RT-PCR. Expression of EphrinB2
was observed increased 2.3-fold (p < 0.01) in MCMV, when
compared to static control (0h), while no such upregulation was
observed in HEMV under the same perfusion rate. Similarly, in
perfused HEMV, EphB4 displayed a more modest, though
Fig. 4. HEMV undergoing neovascularization. (aec) Day 17 panoramic images (10X) of representative embedded HEMV showing angiogenic sprouting throughout fibroblasts
matrices (DAPI). Both GFR-Matrigel® and 4%-GelMA support angiogenesis. Lower right micrograph, 20X confocal orthogonal views showing HEMV remain hollow (arrowhead)
during angiogenic growth. Scale, 500 mm; inset 50 mm. (b) No statistical difference (p > 0.59) between the matrices was observed when comparing the number of naïve sprouts
present/10X field. (c) Sprout lengths from four individual GFR-Matrigel® embedded HEMV were quantified. Lengths varied from 50 to 1290 mm, with a median of 547 mm after 21
days. n ¼ 38 (d) Depicts a panoramic image focusing on a single sprout (center) stained with anti-CD31 (green) and DAPI (blue). Four separate positions along the microvessel (60X)
are also shown. Adjacent orthogonal views show the hollow nature of the sprouts. Inset iii, denoted with an asterisk, shows the displacement of a sprout nucleus to the outer edge of
the sprout. Close inspection of anti-CD31 reveals extensive filopodial projections, indicating continual expansion through 21 days. Scale, 200 mm; inset 25 mm. (e) Upper (10X) and
lower panels (20X) show representative HEMV undergoing neovascularization. Arrowheads depict multiple anastomoses, whereby a single sprout connects with a neighboring
growth. Overlaid images anti-CD31 (green) and DAPI (blue) are shown right. Scale, 50 mm (10X); 25 mm (20X).
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significant 1.4-fold (p < 0.03) increase in response to HEMV
perfusion indicating appropriate identification of a venous-like
microvessel.
In summary, results obtained from perfusion experiments using
the manifold device show that HEMV support perfusion and
respond to shear stress, significantly improving upon in vitro
endothelial networks and acellular microchannel conduits used in
other applications. Additionally, the EphrinB2 and EphB4 bio-
markers distinguish HEMV from MCMV, thus providing biochem-
ical evidence that fabricated microvessels can exhibit differential
responses to the appropriate signaling cue, whether from a growth
factor for an integral signaling pathway such as TGF-beta or shear
stress in response to perfusion.
4. Conclusions
Technological advances in microfluidics combined with
improved biocompatible materials have made microfabrication of
human blood vessels a possibility [20e24,52]. Combining a func-
tional vasculature which displays developmental processes to
support complex tissue constructs is critical, and many of the
developmental process observed in native human blood vessels
have been recapitulated using HEMV technology. In summary,
biochemical and mechanical analyses illustrate that HEMV support
single- or multi-cell attachment and growth; remodel their extra-
cellular matrix by incorporating native human proteins into the
vessel wall; remain hollow/porous tubules of the predesigned size
and function in a matrix of other cells. In addition, HEMV promote
angiogenesis, tubulogenesis and anastomosis together as a single
system within a three-dimensional in vitro tissue model. Further,
perfused HEMV permit the biochemical analyses of HEMV under
various flow conditions. When compared to other constructs, such
as decellularized vessel scaffolds, HEMV reduce the potential
transfer of donor pathogens, are more comparable in size to human
venules/arterioles and are easily positioned into a tissue model.
Most notably, the extensive neoangiogenesis observed from
embedded HEMV and the capacity for long-term storage under-
score the versatility that both freshly prepared and cryopreserved
HEMV provide, allowing the user to design, create and store the
fabricated HEMV for future use. Concerning neoangiogenesis,
importantly we find embedded HEMVs self-vascularize their sur-
rounding ECM eliminating the need to fully ‘engineer’ tissue
vascularization. Rather, the cells present in the HEMV respond to
signaling cues that direct where and to what extent angiogenesis
should occur, which is more representative of the native state of
vascular development. Finally, other technologies such as 3D
Fig. 5. Microfluidic manifold and modeling shear-stress response. (a) Left, diagram of novel microfluidic manifold device; middle, HEMV loaded manifold; right, transmission/Nile
Red microparticles (NRmp, 2 mm O.D.) overlay of HEMV under perfusion. Scale, 1.5 cm and 50 mm, respectively. (b) Live-HEMV were used to perfuse either endothelial growth media
or microparticles in a recirculated fashion using separate microvessels at 4 dyn/cm2. Scale, 50 mm (c) Shear-stress response genes were examined via real-time PCR from growth-
media perfused HEMV. Genes with the most differential regulation include the TGF-b members SMAD6 (downregulated 3.8-fold; p < 0.001) and SMAD7 (upregulated 3.5-fold,
p < 0.001). Other observed changes included SPHK1 (upregulated 3.1-fold; p < 0.001) and SGPL1 (downregulated 1.7-fold; p < 0.05). SGPP1 was observed unchanged. (d and e)
EphrinB2 or EphrinB4 are biomarkers capable of distinguishing arterial from venous blood vessels, respectively. The effect of perfusion on EphrinB2 and EphB4 gene expression was
assessed using either live HEMV or live multi-cell microvessels (MCMV) via real-time PCR. In the arterial-like MCMV, EphrinB2 was observed upregulated 2.3-fold (p < 0.01); while
EphB4 was upregulated 1.4-fold (p < 0.03) in venous-like HMEV in response to growth media perfusion. Statistical analyses shown compare the 2 h perfusion group to static
perfusion 0 h control microvessels. Error bars depict standard error of the mean (SEM) of 3 biological replicates.
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printing, while undoubtedly promising, have yet to produce a hu-
man vascularized model that can exhibit long-term viability,
extensive angiogenesis, perfusion and blood vessel storage. Thus,
HEMV technology provides a level of flexibility and experimental
standardization not possible using endothelial spheroid cultures or
other microvessel technologies.
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